Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Roche has partnered with Regeneron Pharmaceuticals to develop, manufacture and distribute the latter’s antiviral antibody combination, REGN-COV2, as a potential treatment of Covid-19.
REGN-COV2 could help treat patients with symptoms and also prevent the disease in individuals exposed to the virus. The partners expect to boost the supply of the therapeutic by at least three and a half times the existing capacity and may expand even further.
Currently, the drug candidate is undergoing two Phase II / III clinical trials as a Covid-19 treatment and a Phase III trial to prevent the disease in household contacts of infected.